Honokiol enhances the sensitivity of cetuximab in KRAS^G13D mutant colorectal cancer through destroying SNX3-retromer complex.

ABSTRACT: Rationale : the proto-oncogene KRAS is frequently mutated in colorectal cancer (CRC), leading to inherent resistance against monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), such as cetuximab. Therefore, addressing the primary resistance and expanding the indications for target therapy have become critical challenges. Methods : the screening of a natural product library against KRAS mutant CRC cells was conducted, leading to the discovery of a small molecule compound that sensitive to the KRAS^G13D mutation site. The anti-tumor activity of this small molecule compound in combination with cetuximab was evaluated using the KRAS^G13D mutant CRC models both in vivo and in vitro. This evaluation inc

SUBMITTER: Zhu Q 

PROVIDER: S-EPMC11413778 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature